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Insulin degludec/insulin aspart (IDegAsp) is a fixed-ratio co-formulation of insulin
degludec, which provides long-lasting basal insulin coverage, and insulin aspart,
which targets postprandial glycaemia. This review provides expert opinion on the
practical clinical use of IDegAsp, including: dose timings relative to meals, when and
how to intensify treatment from once-daily (OD) to twice-daily (BID) dose adjust-
ments, and use in special populations (including hospitalized patients). IDegAsp could
be considered as one among the choices for initiating insulin treatment, preferential
to starting on basal insulin alone, particularly for people with severe hyperglycaemia
and/or when postprandial hyperglycaemia is a major concern. The recommended
starting dose of IDegAsp is 10 units with the most carbohydrate-rich meal(s),
followed by individualized dose adjustments. Insulin doses should be titrated once
weekly in two-unit steps, guided by individualized fasting plasma glucose targets and
based on patient goals, preferences and hypoglycaemia risk. Options for intensifica-
tion from IDegAsp OD are discussed, which should be guided by HbA1c, prandial
glucose levels, meal patterns and patient preferences. Recommendations for
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switching to IDegAsp from basal insulin, premixed insulins OD/BID, and basal-plus/
basal–bolus regimens are discussed. IDegAsp can be co-administered with other
antihyperglycaemic drugs; however, sulphonylureas frequently need to be discontinued
or the dose reduced, and the IDegAsp dose may need to be decreased when sodium-
glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists are
added. Considerations around the initiation or continuation of IDegAsp in hospitalized
individuals are discussed, as well as in those undergoing medical procedures.
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1 | INTRODUCTION
Type 2 diabetes (T2D) is a complex, progressive disease; many people
require insulin treatment for glycaemic control.1 Basal insulin prod-
ucts are used to supplement residual endogenous insulin secretion
throughout the day and improve fasting plasma glucose (FPG), while
bolus insulins are used to address prandial insulin requirements and
limit postprandial hyperglycaemia. Basal–bolus regimens, where basal
and bolus insulins are administered as separate injections,2 increase
an individual's treatment burden and inconvenience, and may limit
medication adherence.3 To overcome these barriers, premixed insu-
lins can be used, which contain a fixed proportion of protaminated
and non-protaminated (hence soluble) insulin in a single injection.
The protaminated fraction of the insulin undergoes a protracted
absorption from the subcutaneous injection depot into the circula-
tion, whereas the free fraction is rapidly absorbed as an insulin
bolus.4,5 However, premixed insulin formulations have limitations:
accurate dosing is dependent on adequate resuspension; protaminated
insulins still have a shorter duration of action and greater glycaemic var-
iability than basal insulin analogues;6,7 and the absorption kinetics of
the two components are not clearly separated, resulting in a prolonged
and potentially excessive peak glucose-lowering effect compared with
rapid-acting insulins (i.e. a ‘shoulder effect’).8
In recent years, and in light of the aforementioned limitations, fixed-
ratio co-formulation products have been developed. These are com-
posed of two antihyperglycaemic drugs that maintain their distinct phar-
macokinetic (PK) and pharmacodynamic (PD) properties despite being
administered as a co-formulation9 and can allow for a comparatively sim-
ple insulin regimen, with fewer injections and greater flexibility in dosing
time than basal-plus/basal–bolus therapy.3 Available fixed-ratio co-
formulations include insulin degludec/insulin aspart (IDegAsp),10 insulin
degludec/liraglutide11 and insulin glargine/lixisenatide.12
IDegAsp is the first fixed-ratio co-formulation of two different
insulin analogues, comprising insulin degludec (degludec) (70%), a
basal insulin analogue with an ultra-long duration of action, and
rapid-acting insulin aspart (IAsp) (30%),10 thereby providing basal
and prandial insulin cover when administered with meals.4 Combin-
ing two analogues together has not previously been possible
because of either incompatibilities in the required pH of the
formulation (with insulin glargine13,14), or the formation of hybrid
insulin hexamers (with insulin detemir15), with unpredictable PK
profiles. Unique to degludec is the assembly of dihexamers that
are held together by side-chain zinc contacts, forming a highly sta-
ble structure.16 At high zinc concentrations, there is probably little
or no association between degludec monomers and monomers of
the co-formulated IAsp, either in the formulation or the injection
depot.16,17 The resulting soluble product has a superior PK profile
to that of conventional premix insulins, reflecting the flat and pro-
longed stable levels of basal insulin achieved by the degludec com-
ponent, and a clear separation of the bolus component; thus there
is no observed ‘shoulder effect’ with IDegAsp (Figure 1).16,18
IDegAsp has been extensively investigated in people with T2D
(Table 1),19–27 and also in people with type 1 diabetes (T1D),
through the BOOST clinical trial programme.28–30 Previous guid-
ance on the use of IDegAsp has been published.31–33 This guid-
ance, however, is limited and does not address common challenges
in clinical use such as dose timing relative to meal(s), whether
IDegAsp should be administered once daily (OD) or twice daily
(BID), when and how to intensify treatment from OD to BID
(dosage splitting) and dose adjustments. Additionally, there is lim-
ited guidance on the use of IDegAsp in hospitalized patients,
elderly people and children. Although general guidance on the
management of hyperglycaemia in T2D is provided in the American
Diabetes Association/European Association for the Study of
Diabetes (ADA/EASD) 2018 consensus report34 and the ADA
2020 Standards of Medical Care in Diabetes recommendations,35
the treatment recommendations may not be applicable to all
patient populations. We provide expert opinion on the use of
IDegAsp in light of the limited guidance available for this treat-
ment in the management of hyperglycaemia in T2D.
2 | METHODOLOGY
This article addresses the clinical use of IDegAsp; these recommenda-
tions are based on global trial evidence combined with the extensive
multinational clinical experience of the authors. To support these recom-
mendations, relevant clinical and trial evidence was obtained through a
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literature review, with PubMed and ProQuest searches for articles publi-
shed from 10 April 2009 to 09 April 2019 (see the supporting informa-
tion), and the results were discussed by the author group.
3 | MAIN MEAL CONCEPT
When starting IDegAsp treatment, it is administered with the main
meal(s) of the day,10,24,37 generally regarded as the most
carbohydrate-rich meal(s).27 The flexibility in dose timing of IDegAsp
allows the main meal to be eaten at any time during the day.10,32
However, if a dose is missed, it should be taken with the next main
meal of that day; an extra dose should not be taken at any other time
to compensate for a missed dose.10 After the missed dose is taken,
the usual dosing schedule should be resumed.10
The main meal is usually the evening meal; however, based on
clinical practice, in some regions (e.g. Mexico, parts of India and other
regions), the main meal is often the midday meal. Despite the main
meal being the evening meal in Japan, IDegAsp is often administered
before breakfast as part of BID regimens, as this may promote adher-
ence.38 In our experience, adherence in OD regimens may also be
improved with IDegAsp administration at breakfast. Therefore, the
main meal concept is recommended to determine dose timings as per
the label, but in clinical practice other factors may also contribute.
In summary, the timing of IDegAsp administration should be
based on the carbohydrate content of the meal (main meal concept).
However, considerations around promoting compliance (adherence
strategy) may also influence optimal injection timing.
4 | INITIATION WITH IDegAsp
Because of the progressive nature of T2D, intensification from max-
imum tolerated doses of oral antidiabetic drugs (OADs) to injectable
glucose-lowering therapy eventually becomes necessary in many
people.39 The ADA/EASD 2018 guidelines and ADA 2020 Stan-
dards of Medical Care in Diabetes recommend a glucagon-like
peptide-1 receptor agonist (GLP-1RA) as the first choice for people
with T2D who require injectable therapy.34,35 This recommendation
is based on the lower risk of hypoglycaemia compared with basal
insulin, and potential weight-sparing effect with these agents.40,41
For people at high risk of cardiovascular disease (CVD), the selec-
tion of a GLP-1RA with proven cardiovascular benefit as the first
choice is particularly important.35 Of note, however, for people with
HbA1c >11.0% (97 mmol/mol)34 or evidence of catabolism, a GLP-
1RA is not ideal, and insulin is recommended as the first injectable
therapy.35 Based on clinical experience, country-dependent limita-
tions in access to these drugs, driven by high costs, also influence
medication use, particularly where they are not reimbursed by
health authorities.
We recommend that IDegAsp OD could be considered as one
among the choices for initiating insulin treatment for people with
T2D.31,32 This fixed-ratio insulin co-formulation may be preferable to
initiating basal insulin alone, particularly for people in whom extreme
and symptomatic hyperglycaemia is a major concern, and in whom
postprandial hyperglycaemia is an additional concern. Based on clini-
cal experience, we recommend that intensification to IDegAsp OD
may also be appropriate in people with a low body mass index (BMI),
in whom weight gain is less of a concern, and whose lower BMI may
reflect beta-cell insufficiency, which is likely to necessitate insulin
therapy.42 However, for people with obesity, established CVD, at high
risk of CVD or with diabetic kidney disease, a GLP-1RA may be more
suitable, as discussed above.
We would consider initiating IDegAsp OD in people with HbA1c
≥ 7.0% (53 mmol/mol) and postprandial glucose ≥180 mg/dL
(10.0 mmol/L) already on maximum OAD therapy. However, if fasting
blood glucose levels are low (<100 mg/dL [5.6 mmol/L]), basal insulin
would not be the therapy of choice. The rationale for our
F IGURE 1 Comparison of mean glucose infusion rate of
(A) IDegAsp and (B) BIAsp 30 in patients with T1D.18 BIAsp 30,
biphasic insulin aspart 30; IDegAsp, insulin degludec/insulin aspart co-
formulation; T1D, type 1 diabetes; U, units. Figure reproduced with
permission from Unnikrishnan AG et al. J Assoc Physicians India.
2015;63:15-20. © Association of Physicians of India, 2015,18 and
from Heise T et al. Diabetes, American Diabetes Association, 2013.
Copyright and all rights reserved. Material from this publication has
been used with the permission of American Diabetes Association.36
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TABLE 1 Key phase III clinical trials of IDegAsp in T2D
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TABLE 1 (Continued)
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TABLE 1 (Continued)
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TABLE 1 (Continued)
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Abbreviations: BIAsp 30, biphasic insulin aspart 30; BID, twice daily; CI, confidence interval; DPP-4i, dipeptidyl-peptidase-4 inhibitor; ERR, estimated rate
ratio; ETD, estimated treatment difference; glargine, insulin glargine; glargine U100, insulin glargine 100 units/mL; IAsp, insulin aspart; IDegAsp, insulin
degludec/insulin aspart co-formulation; IGlar, insulin glargine; NPH, insulin neutral protamine Hagedorn; NS, not significant; OAD, oral antidiabetic drug;
OD, once daily; OW, once weekly; SD, standard deviation; SGLT-2i, sodium-glucose co-transporter-2 inhibitor; SU, sulphonylurea; TID, three times daily;
T2D, type 2 diabetes; Q2W, every 2 weeks.
*The mean ETD (IDegAsp–glargine U100) was −0.08% (95% CI: −0.26, 0.09) after 52 weeks, as observed in the core phase at week 26.24
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recommendation is that starting a fixed-dose combination addresses
both of these concerns simultaneously (case study 1); the IAsp com-
ponent targets postprandial glucose and the degludec basal compo-
nent provides a stable glucose-lowering effect with less variability
over 24 hours compared with other basal insulins.43 This advantage
over basal insulin has been shown in insulin-naïve people with T2D
treated with IDegAsp compared with insulin glargine 100 units/mL
(IGlar U100). After 26 weeks of treatment, insulin-naïve participants
treated with IDegAsp experienced superior reductions in HbA1c com-
pared with IGlar U100 (estimated treatment difference [ETD]:
−0.28% [−0.46; −0.10]95% confidence interval [CI], P < .01) (Table 1).
21 In
another trial, reductions were observed in post-evening meal, but not
post-breakfast or post-midday meal, glucose excursions with IDegAsp
versus IGlar U100, and nocturnal glycaemia was more stable after
16 weeks.37 Furthermore, it is reasonable to extrapolate the improve-
ment in glycaemic variability previously reported with degludec to
IDegAsp; the effect of the basal component of IDegAsp has been
observed to be less variable,43 as inferred from the lower rates of noc-
turnal hypoglycaemia (00:01 AM to 05:59 AM) with IDegAsp versus
basal–bolus therapy (IGlar U100 + IAsp) in the Step-by-Step trial.27
Similarly, rates of hypoglycaemia were 58% lower at 16 weeks with
IDegAsp BID compared with biphasic insulin aspart 30 (BIAsp 30) BID
initiation, despite similar HbA1c reductions.44
The recommended starting total daily dose of IDegAsp is 10 units
with meal(s), followed by individual dose adjustments.10 In cases of
severe hyperglycaemia (HbA1c >10% [86 mmol/mol]), a higher initial
dose of IDegAsp may be used, at the clinicianʼs discretion. Similarly,
body weight should also be considered when initiating dosing of
IDegAsp; 0.3 units/kg is recommended for premix insulin in the 2018
ADA/EASD guidelines,34 although this information is omitted from the
2020 ADA guidelines. Titration of IDegAsp should be individualized
based on patient preference and goals, and the risk of adverse
events.10,34 To guide insulin dose titration, individualized FPG targets
are used, and titration is typically carried out in two-unit steps
(Figure 2). Postprandial glucose levels are not usually considered when
determining titration algorithms. Titrating once weekly is advisable in
the majority of people because of the long half-life of degludec;4,10
individuals should be advised that it can take up to 48–72 hours for
degludec to reach steady state,45 so dose changes should not be made
before this.
Regular self-monitoring of blood glucose (SMBG), or 24-hour glu-
cose monitoring if available, should be used to guide dose adjustments
and to assess response, particularly at initiation. Ideally, self-
monitoring should be started immediately, and should initially be mea-
sured before breakfast, before evening meal and during the night. Pre-
treatment monitoring is also desirable, to provide a baseline for
comparison. However, pragmatic approaches to self-monitoring may
be warranted: for example, in elderly people initiating small doses,
who may have trouble with the burden of learning simultaneously to
self-inject and take measurements.
Clinical trials of IDegAsp have used a stringent FPG target of
71–90 mg/dL (4.0–5.0 mmol/L) with once-weekly dose adjustments
of 2–8 units (Figure 2).27 However, for people at higher cardiovascular
risk, a less stringent FPG target of 91–126 mg/dL (5.0–7.0 mmol/L)
has been used.46 Based on real-world experience, we recommend that
a target of 80–130 mg/L (4.4–7.2 mmol/L) might be appropriate in
clinical practice. Titration regimens must therefore be adjusted to
reflect both individualized targets and patient characteristics
(e.g. obesity, age or renal dysfunction). We recommend that monitor-
ing should be continued at least twice weekly until the individualized
target FPG is reached. More frequent monitoring may be needed
depending on clinical context, or for specific purposes such as con-
firming fitness to drive.
5 | INTENSIFICATION FROM IDegAsp OD
If adequate glycaemic control is not achieved with IDegAsp OD, treat-
ment can be intensified to (a) IDegAsp BID, (b) IDegAsp OD plus pran-
dial IAsp at one or more meals, if the postprandial target is not met, or
(c) IDegAsp BID, plus a single dose of IAsp at the third meal. If
required, intensification from IDegAsp OD should not be delayed and
should be guided by HbA1c, prandial glucose levels, meal patterns and
patient preference. In the 38-week Step-by-Step trial, people with
T2D and inadequate glycaemic control on basal insulin were random-
ized to receive IDegAsp OD or IGlar U100 + IAsp OD for 26 weeks,
with dose intensification to IDegAsp BID or IGlar U100 + IAsp BID/-
three times daily (TID) at weeks 26 and 32, respectively, if HbA1c tar-
gets of <7.0% (53 mmol/mol) were not met (Table 1).27
F IGURE 2 IDegAsp initial titration algorithm used in the phase III
clinical trial programme.27 IDegAsp, insulin degludec/insulin aspart co-
formulation; U, units
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At week 38, reductions in HbA1c were similar in both arms (ETD:
0.09% [−0.04; 0.22]95% CI).
27
Intensification to IDegAsp BID is recommended if there are post-
prandial glucose excursions after two meals in 1 week and the excur-
sions are unresponsive to diet manipulation. The maximum
permissible dose of IDegAsp is limited by the IAsp dose required for a
particular meal by the patient, as well as the FPG target (case study 2).
We recommend a maximum OD dose of 30–40 units before splitting
the dose. When intensifying to BID, the total daily dose of IDegAsp
OD is split over two doses, administered at the two meals with the
greatest carbohydrate content,10,27 with a minimum dosing interval of
4 hours. The dose ratio (not necessarily 1:1) should be based on the
relative carbohydrate content of the meals and the postprandial glu-
cose excursion following each meal.
Further intensification from IDegAsp OD to IDegAsp BID, with a
single dose of IAsp at the main meal, is recommended if there are per-
sistent excessive postprandial glucose excursions (i.e. three readings
of ≥180 mg/dL [≥10.0 mmol/L] over 1 week on SMBG or capillary
blood glucose; however, this may vary with individualized targets and
monitoring frequency). Intensification to IDegAsp OD with IAsp BID
after the two largest meals of the day may also be an option where
persistent postprandial hyperglycaemia occurs in combination with
normalized FPG: for example, in countries where meals are typically
rich in carbohydrate.
Although degludec has a duration of action longer than 42 hours
at steady state, BID administration of IDegAsp does not result in accu-
mulation of degludec because the same steady-state level is reached
in the circulation with a given total daily dose of degludec whether it
is administered OD or BID.4,43,47 This has been supported by simu-
lated steady-state PD modelling, which has suggested that dividing
the IDegAsp dose in two provides the same basal glucose-lowering
effect as OD dosing.48,49 Additionally, IDegAsp BID theoretically pro-
vides a better distribution of insulin versus IDegAsp OD to manage
postprandial excursions.
6 | SWITCHING TO IDegAsp FROM OTHER
TREATMENT REGIMENS
6.1 | Switching from basal insulin
There are several important considerations when assessing the effec-
tiveness of basal insulin treatment. The first consideration, often over-
looked, is whether the patient is happy with their current regimen.
Increasing doses of basal insulin without consideration of alternative
therapies is common, and may lead to clinical inertia and prolonged
poor glycaemic control. The second consideration is whether basal
insulin offers appropriate glycaemic control; if HbA1c levels are ele-
vated in the context of normal pre-breakfast FPG levels, this indicates
postprandial hyperglycaemia and should trigger reassessment of the
most suitable insulin regimen.
IDegAsp may be considered for treatment intensification in peo-
ple with T2D with inadequate glycaemic control on basal insulin. The
Step-by-Step trial investigated the use of IDegAsp as an intensifica-
tion option from basal insulin with or without OADs.27 During the
26-week treatment-initiation phase of the Step-by-Step trial, people
with T2D and inadequate glycaemic control on basal insulin who were
randomized to receive IDegAsp OD or IGlar U100 OD + IAsp OD
achieved similar reductions in HbA1c (ETD: 0.07% [−0.06; 0.21]95% CI)
with similar overall hypoglycaemia.27 However, in another randomized
study that showed the non-inferiority of glycaemic control with
IDegAsp compared with target-titrated intensification of IGlar U100,
IDegAsp led to higher rates of overall hypoglycaemia than IGlar U100
(estimated rate ratio [ERR]: 1.43 [1.07; 1.92]95% CI, P < .05), with no
significant difference in rates of nocturnal hypoglycaemia (ERR: 0.80
[0.49; 1.30]95% CI, P = NS) (Table 1).
25 However, in this trial, IDegAsp
was not necessarily administered with the largest meal of the day,
hence injection of IDegAsp in some participants could have triggered
postprandial hypoglycaemia. In a similar study in Japanese people with
T2D, IDegAsp was consistently administered with the largest meal,
and the rates of overall and nocturnal hypoglycaemia with IDegAsp
were comparable with IGlar U100 (ERR IDegAsp/IGlar U100: 0.73
[0.50; 1.08]95% CI, P = NS, and 0.75 [0.34; 1.64]95% CI, P = NS, respec-
tively) (Table 1).21
Furthermore, if nocturnal hypoglycaemia is a problem with basal
insulin, switching to IDegAsp may be preferable. In the Step-by-Step
trial,27 similar glycaemic control was achieved with IDegAsp OD com-
pared with IGlar U100 OD + IAsp OD, with significantly fewer noctur-
nal episodes (ERR: 0.61 [0.40; 0.93]95% CI) (Table 1).
27 We recommend
a threshold of 36–40 units of basal insulin, or 0.5 IU/kg/day,50 after
which, if glycaemia is still insufficiently controlled (HbA1c ≥7.0%
[53 mmol/mol], postprandial glucose ≥180 mg/dL [≥10 mmol/L]),
alternative treatments, including IDegAsp, should be considered. An
important consideration when switching from basal insulin to IDegAsp
is that the unit-for-unit conversion is not necessarily 1:1; therefore,
the dose may need to be reduced for those experiencing
hypoglycaemia or for those previously on insulin glargine
300 units/mL (case study 3).
6.2 | Switching from premix insulins OD/BID/TID
People receiving BIAsp 30 may benefit from switching to IDegAsp if
glycaemic control is suboptimal or if they are experiencing
hypoglycaemia. In addition to a superior PK/PD profile, with clearer
separation of the basal and prandial components (Figure 1), IDegAsp
also has the advantage of being presented in a soluble co-formula-
tion, hence resuspension before administration is not required,4,19
in contrast to premixed insulin formulations.16,51 These properties
can be expected to help mitigate the risk of hypoglycaemia. A
26-week trial, in which people were switched to IDegAsp or BIAsp
30 from their previous insulin regimen, showed lower rates of over-
all and nocturnal hypoglycaemia at similar HbA1c and improved
FPG levels with IDegAsp than with BIAsp 30 (Table 1).19 Prior to
trial initiation, participants were receiving premixed human or ana-
logue insulin or self-mixed insulin regimens containing 20–40%
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fast-/rapid-acting component.19 When switching from BIAsp 30 OD
to IDegAsp, a unit-for-unit conversion may be used if the person
has suboptimal glycaemic control (i.e. HbA1c >8.0% [64 mmol/
mol]). If individuals are receiving BIAsp 30 BID, a unit-for-unit con-
version of the total daily dose may be split over IDegAsp BID,
administered with main meals; for individuals treated with BIAsp
30 TID, this may be split over IDegAsp BID at main meals, with or
without an additional IAsp dose to cover the third meal (case study
4). However, if the HbA1c level is ≤8.0% [64 mmol/mol] or the
patient is experiencing hypoglycaemic episodes, the initial dose of
IDegAsp should be reduced by 10–20% compared with the original
BIAsp 30 dose.38
6.3 | Switching from a basal-plus/basal–bolus
regimen
IDegAsp is suitable for people who do not want to or cannot take
multiple injections each day, and therefore provides an alternative to
basal–bolus regimens. In a randomized trial in people with T2D,
patient-reported outcome scores for social functioning were signifi-
cantly higher for IDegAsp BID versus degludec OD + IAsp 2–4 times
daily (ETD: 2.2 [0.3; 4.1]95% CI, P < .05).
52 Although non-inferiority
was not confirmed for mean change in HbA1c, there was no statisti-
cally significant difference between the treatment groups in either
glycaemic control or hypoglycaemia. Therefore, the improvement in
patient-reported outcome scores was probably a result of the reduced
burden of injections with IDegAsp BID versus a basal–bolus regimen
(degludec + IAsp). In the Step-by-Step trial, treatment could be inten-
sified following visits at weeks 26 and 32 if HbA1c was not on target
in the previous week (target: <7%).27 Those receiving IDegAsp could
be intensified to IDegAsp BID, and those receiving IGlar U100 OD
+ IAsp OD had the option of intensification to IGlar U100 OD + IAsp
BID/TID (Figure 3).27 IDegAsp OD/BID achieved similar glycaemic
control with significantly less nocturnal hypoglycaemic at a lower
insulin dose and with fewer daily injections compared with IGlar U100
OD + IAsp OD/BID/TID.27
Switching from a basal–bolus regimen needs to be individualized
to the patient, based on careful consideration of basal–bolus doses
and detailed blood-glucose monitoring, with close ongoing assessment
(case study 5). Other clinicians should be encouraged to seek advice
from a diabetes specialist before undertaking such a change.
7 | CO-ADMINISTRATION WITH OTHER
ANTIDIABETIC MEDICATIONS
IDegAsp can be used in combination with most OADs.10 In our experi-
ence, if sodium-glucose co-transporter-2 (SGLT-2) inhibitors are
added to IDegAsp, the insulin dose should be decreased by 10–20%;
for people already receiving an SGLT-2 inhibitor, IDegAsp may be ini-
tiated and subsequently titrated weekly to reduce the risk of side
effects. People using SGLT-2 inhibitors should be aware of, and fol-
low, local guidelines on sick day rules.
Caution should also be taken when combining IDegAsp with
sulphonylureas (SUs). We recommend that, for people receiving
F IGURE 3 The Step-by-Step trial design for treatment intensification.27 *Treatment intensification period was followed by 1-week washout
period and then 30-day follow-up period; OADs included: metformin, DPP-4i, SGLT-2i, αGI (SU/glinides were discontinued at randomization).
ɑGI, alpha-glucosidase inhibitor; BID, twice daily; DPP-4i, dipeptidyl peptidase 4 inhibitor; IAsp, insulin aspart; IDegAsp, insulin degludec/insulin
aspart; IGlar U100, insulin glargine U100; OAD, oral antidiabetic drug; OD, once daily; T2D, type 2 diabetes; TID, three times daily; TZD,
thiazolidinedione; SGLT-2i, sodium-glucose co-transporter inhibitor; SU, sulphonylurea. Reprinted and adapted from Philis-Tsimikas et al. Diabetes
Res Clin Pract. 2019;147:157-165, © 2019 with permission from Elsevier.27
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IDegAsp BID, SUs should be discontinued; with IDegAsp OD, SU
treatment may need to be discontinued or the dose reduced.
The long-term effects of pioglitazone use alongside insulin treat-
ment are still uncertain. The combination has been associated with
the development of heart failure in some people with longstanding
T2D and heart disease or a previous stroke.10 However, a recent sys-
tematic review suggested that pioglitazone is a feasible adjunct to
insulin therapy.53 In addition, recent data showed that pioglitazone in
combination with insulin may reduce the risks of all-cause mortality
and non-cardiovascular death in people with T2D.54
No additional considerations are required when combining
IDegAsp with metformin, α-glucosidase inhibitors or dipeptidyl
peptidase-4 inhibitors (DPP-4is), which can all be continued at the
same dose when IDegAsp is added.
Based on our experience, when adding IDegAsp to a GLP-1RA,
there is usually no decrease in insulin dose; an initial daily dose of
10 units is recommended. However, if a GLP-1RA is added to
IDegAsp, the insulin dose may need to be decreased,10 depending on
HbA1c levels (e.g. if HbA1c <7.5% [59 mmol/mol]).
8 | PATIENT PROFILES
There are specific considerations when using IDegAsp in certain
populations, with common patient groups considered below. Additional
recommendations for people with T2D undertaking religious fasting,
and for children with T1D, can be found in the supporting information.
8.1 | Use in adults with T1D
In adults with T1D, IDegAsp OD as part of a simplified basal–bolus
regimen with mealtime IAsp improved overall glycaemic control and
was non-inferior to insulin detemir (IDet) OD + mealtime IAsp basal–
bolus therapy.28 Treatment with IDegAsp also incurred a compara-
tively reduced risk of nocturnal hypoglycaemia.28 Recommendations
for children with T1D can be found in supplementary case study 1.
8.2 | Use in adolescents with T2D
The incidence of T2D in adolescents has increased globally in recent
decades,55–57 which has been linked to obesity.58 The rapid decline of
beta-cell function in adolescents59,60 merits the use of insulin treat-
ment. Indeed, initial treatment with metformin and/or insulin alone or
in combination is recommended in adolescents with T2D and marked
hyperglycaemia (blood glucose ≥250 mg/dL [>13.9 mmol/L] and/or
HbA1c ≥8.5% [69 mmol/mol]).61
Although IDegAsp has not been the subject of clinical trials in
adolescents with T2D, an efficacy and safety evaluation has been
made using data from adolescent and adults with T1D and adults with
T2D. This assessment supports the use of IDegAsp in adolescents
with T2D.10
8.3 | In-hospital use
Rapid-acting insulin (preferentially as part of a basal–bolus regimen) is
generally used when the patient is hospitalized and is preferred to
combination insulins because of greater flexibility for titration. The
decision as to whether IDegAsp should be continued or switched to
another medication after admission to hospital is often made by the
hospital group. In some regions, IDegAsp is discontinued because
titration is not practical for inpatients because of the time needed for
the degludec component to reach steady state, and the fixed ratio of
the IAsp content (see supplementary case study 2). This may be perti-
nent when there are changes to diet, appetite, cases of sepsis or a
need to take corticosteroids. An IDegAsp-based insulin regimen can
be initiated or restarted when the patient is discharged.
Peri-operative recommendations are region-specific. Based on
the authorsʼ experiences, for minor procedures, for example, cata-
ract surgery, no dose alteration may be needed if the patient is able
to eat normally; otherwise, IDegAsp may be omitted, or switched
to degludec (if available), IGlar or IDet on the operation day. For
major operations, IDegAsp treatment should be discontinued
24 hours before the operation. In instances of prolonged fasting,
for example for colonoscopy, the insulin dose may need to be
decreased by ≈30–50% ≈3 days before the procedure. People may
be switched from IDegAsp to insulin basal–bolus regimens, or basal
regimens with corrective rapid-acting insulin, during the peri-
operative period.62
8.4 | Use in people with renal impairment
IDegAsp is suitable for people with renal impairment.10 Glucose moni-
toring should be intensified and the insulin dose adjustments individu-
alized.10 As reduced renal clearance of basal insulin may result in
hypoglycaemia in those with severe impairment, the decision to use
IDegAsp over rapid-acting insulin should be made on an individual
basis, accounting for the degree of residual renal function. Extra cau-
tion is needed in individuals undergoing dialysis treatment, consider-
ing the frequency and modality of dialysis.
8.5 | Elderly people
There are several concerns when treating elderly people with diabe-
tes. The symptoms of hypoglycaemia can be particularly debilitating in
elderly people because of frailty, and hypoglycaemia has been associ-
ated with an increased risk of fall-related events in elderly people who
experienced hypoglycaemia compared with those who did not experi-
ence hypoglycaemia.63
A retrospective cohort study of people with T2D aged 60 years or
older showed that mortality risk was lower for people with HbA1c 6.0–
9.0% (42–75 mmol/mol) compared with those with an HbA1c of less
than 6% (42 mmol/mol).64 Additionally, post hoc analysis of data from
the ACCORD trial showed that a 1-year increment in baseline age was
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associated with a 3% increase in the risk of severe hypoglycaemia
(P < .0001).65 For elderly people with frailty and multiple co-morbidities,
less stringent HbA1c targets (<8% or ≤9% [<64 or ≤75 mmol/mol]) than
those used for younger people may be adequate.66
The convenience of a single injection pen and reduced number of
injections with IDegAsp compared with basal–bolus therapy is likely
to be advantageous in elderly people.3 Many elderly people are
treated in nursing homes or at home by visiting nurses. The arrival
times of nurses may not be consistent; therefore, flexibility in dose
timing may be advantageous. IDegAsp can be administered at differ-
ent times from day to day, provided it is coordinated with a main
meal; this improved flexibility for mealtime variation may be consid-
ered an advantage of IDegAsp compared with other insulin regimens.
A recent post hoc subgroup analysis showed that, in people with
T2D aged 65 years or older, IDegAsp provided effective glycaemic
control consistent with the effects of BIAsp 30, with no significant dif-
ferences in overall confirmed or nocturnal hypoglycaemic events.67
These results were broadly in line with those in the overall popula-
tion.22 However, SUs, if taken, should be discontinued when IDegAsp
treatment is started, because of the increased risk of hypoglycaemia.31
9 | CONCLUSIONS
IDegAsp provides basal as well as prandial insulin cover in a single
injection when administered with a meal. The co-formulation provides
dosing flexibility and may allow fewer injections compared with
basal–bolus regimens.
We recommend IDegAsp as one among the choices for first insu-
lin treatment for people with diabetes when insulin is indicated, and
for whom weight loss is not a priority and access to medication is a
concern. A GLP-1RA is recommended as the first injectable treatment
for people at high risk of CVD.
Clinical evidence supports the use of IDegAsp in a wide variety of
patient populations and can be used for either insulin initiation or
intensification.
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Case studies
The following are based on real case studies that the authors have
been involved with and for which IDegAsp was considered as poten-
tially beneficial for the individual. Patient names and some minor demo-
graphic details have been changed to protect patient confidentiality.
Case study 1. Intensification from OADs
Sara is a 43-year-old woman with a 7-year history of T2D and
no known diabetes complications. Her BMI is 30.8 kg/m2 and she
has arterial hypertension and dyslipidaemia, controlled using treat-
ment with enalapril and atorvastatin. Her HbA1c was 8.8%
(73 mmol/mol) despite maximal doses of metformin and an SU, with
significant postprandial hyperglycaemia. Her diabetes specialist dis-
cussed treatment options and decided to start her on IDegAsp
10 units OD with her main evening meal. Her metformin was contin-
ued at the same dose, and her SU dose was reduced. Sara undertook
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regular SMBG monitoring, and adjusted her dose weekly. After
4 months, her mean FPG and postprandial plasma glucose (PPG) values
were 103 mg/dL (5.7 mmol/L) and 138 mg/dL (7.7 mmol/L), respec-
tively, with IDegAsp 18 units OD.
Case study 2. Intensification from IDegAsp OD to BID
Jane is aged 57 years, has a duration of T2D of ≈10 years and her
BMI is 28.3 kg/m2. She currently takes IDegAsp 32 units OD with her
main meal (degludec 22.4 units, IAsp 9.6 units). However, her FPG
levels were still uncontrolled (184 mg/dL [10.2 mmol/L]) and an
increase in the basal insulin component to 28 units was considered.
One injection of IDegAsp providing 28 units of basal insulin
would correspond to an IAsp dose of 12 units (total IDegAsp dose
40 units). To target the FPG without risking hypoglycaemia, Jane was
advised to split her IDegAsp dose across the two largest meals of the
day, resulting in a total dose of 28 units with her main meal (degludec
19.6 units, IAsp 8.4 units) and 12 units with a second meal (IDeg
8.4 units, IAsp 3.6 units). By dividing the doses, Jane benefitted from
covering two meals with rapid-acting insulin (to better target post-
prandial glycaemia) without running the risk of hypoglycaemia.
Case study 3. Switching from basal insulin to IDegAsp OD
1. Paul is an athlete who has had T2D for 11 years. He has avoided
any diabetes-related complications and has an excellent metabolic
profile with a BMI of 26 kg/m2, blood pressure of 122/60 mmHg
and a resting pulse rate of 56 beats per minute. Paul was previ-
ously treated with IGlar U100 25 units. He has to manage his risk
of hypoglycaemia carefully, especially when training. When
switching to IDegAsp, Paulʼs doctor advised an initial dose reduc-
tion. Paul initiated IDegAsp 20 units OD with the main meal of the
day, with careful blood glucose monitoring. He managed his FPG
to average 100.8 mg/dL (5.6 mmol/L) and PPG levels were
maintained at 133.2 mg/dL (7.4 mmol/L) without any hyp-
oglycaemic events. After 2 weeks, Paul increased his dose to
26 units to ensure he could maintain these levels. This translated
to an HbA1c level of 6.8% within 3 months.
2. Yoshio, a 56-year-old patient with T2D, had been administering
IGlar U300 46 units OD to control his FPG in addition to metfor-
min 1 g BID with dapagliflozin 10 mg OD. He has had T2D for
5 years and has suffered from hypertension and hyperlipidemia, in
addition to being treated for stable angina. When switching to
IDegAsp OD, Yoshio was advised to reduce the dose by 20%
initially, as his initial basal insulin was a high-concentration formu-
lation without a postprandial component. He therefore initiated
IDegAsp at a dose of 36 units and then managed to achieve his
individualized FPG target of 110 mg/dL (6.1 mmol/L) after a fur-
ther reduction of the dose to 32 units OD.
3. Steven, a 52-year old lawyer who has had T2D for 8 years, was
treated with IGlar U100 36 units OD and mealtime IAsp (≤3 times
a day; 6–8 units/meal); his HbA1c was 10.4% (90.2 mmol/mol).
However, he frequently omitted prandial IAsp because of a busy
lifestyle and felt that he was not controlling his disease. Changes in
lifestyle were recommended and Steven was switched to IDegAsp
OD to simplify his treatment regimen, with improving glycaemic
control as his primary aim. Stevenʼs doctor advised that when
switching to IDegAsp, he should use a unit-to-unit dose conversion
of the basal insulin component. He therefore commenced IDegAsp
OD 36 units with his main evening meal and his glycaemic control
improved (mean FPG 149 mg/dL [8.3 mmol/L] and PPG 223 mg/dL
[12.4 mmol/L], HbA1c 8.2%).
Case study 4. Switching from premixed insulin regimens
John is a 63-year old doctor who has had T2D for at least
11 years. He is taking metformin (2 g) and BIAsp 30 (premix) 22 units
BID, and his HbA1c was 8.1% (65 mmol/mol); he frequently omitted
morning insulin doses because of work commitments and reported
nocturnal symptoms of hypoglycaemia. He was switched to IDegAsp
with a unit-for-unit dose conversion: IDegAsp 22 units BID. This was
reduced to 22 units in the morning and 19 units in the evening after a
pre-evening meal blood glucose level of <70 mg/dL (<3.9 mmol/L).
After 4 months, his HbA1c, FPG and postprandial blood glucose
improved, with no further hypoglycaemic symptoms.
Case study 5. Switching from basal–bolus insulin regimens
Paula, aged 65 years, was treated with a basal–bolus insulin reg-
imen (neutral protamine Hagedorn [NPH] insulin 35/26 units BID
and IAsp 5 units BID) and metformin (850 mg BID). Three months
later, her FPG and HbA1c remained persistently high (mean FPG
190 mg/dL [10.5 mmol/L], HbA1c 8.3%). She struggled with fre-
quent injections and irregular mealtimes, sometimes missing doses.
Her regimen was simplified to IDegAsp BID; her previous total dose
was 71 units (NPH 61 units, IAsp 12 units) but, given the potential
for increased adherence and a greater administered dose, her endo-
crinologist advised a 20% reduction in the prescribed dose. Thus,
she initiated IDegAsp BID (28 units/28 units) with the two main
meals. Paula missed fewer doses with her new treatment and her
HbA1c improved.
SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of this article.
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